Docoh
Loading...

GBT Global Blood Therapeutics

News

Pro users get this 30m faster
See Why Jefferies Sees Massive Upside In Global Blood Therapeutics
7 Oct 21
Biotech, Long Ideas, News, Health Care, Price Target, Initiation, Small Cap, Analyst Ratings, Movers, Trading Ideas, General
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
7 Oct 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Jefferies Initiates Coverage On Global Blood Therapeutics with Buy Rating, Announces Price Target of $68
7 Oct 21
News, Price Target, Initiation, Analyst Ratings
Jefferies analyst Akash Tewari initiates coverage on Global Blood Therapeutics (NASDAQ:GBT) with a Buy rating and announces Price Target of $68.
12 Health Care Stocks Moving In Wednesday's After-Market Session
6 Oct 21
Movers
Gainers TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 5.4% to $2.73 during Wednesday's after-market session. The company's market cap stands at $35.2 million.
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
1 Oct 21
Biotech, News, Penny Stocks, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30)
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
28 Sep 21
Biotech, News, Penny Stocks, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27)
Global Blood's Sickle Cell Medicine Under FDA Review For Expanded Use
7 Sep 21
Biotech, News, Health Care, Small Cap, General
Global Blood Therapeutics Announces FDA Has Accepted For Priority Review Supplemental New Drug Application For Oxbryta
7 Sep 21
Biotech, General
New Drug Application for Oxbryta dispersible tablets also accepted for priority review Approximately 17,000 children ages 4 to 11 years have sickle cell disease in the United States SOUTH SAN FRANCISCO, Sept. 07, 2021
Return on Capital Employed Insights for Global Blood Therapeutics
20 Aug 21
Earnings
After pulling data from Benzinga Pro it seems like during Q2, Global Blood Therapeutics's (NASDAQ:GBT) reported sales totaled $47.55 million. Despite a 7.22% in earnings, the company posted a loss of $65.91 million.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19)
88 Biggest Movers From Yesterday
5 Aug 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
Global Blood Shoots 17% Higher As Q2 Earnings Beat Estimates; Analyst Upgrades Stock
4 Aug 21
Biotech, Earnings, Long Ideas, News, Guidance, Upgrades, Health Care, Price Target, Small Cap, Analyst Ratings, Movers, Trading Ideas, General
58 Stocks Moving In Wednesday's Mid-Day Session
4 Aug 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers
Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2021
4 Aug 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
4 Aug 21
Pre-Market Outlook, Markets, Movers
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
4 Aug 21
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3)
Truist Securities Upgrades Global Blood Therapeutics to Buy, Raises Price Target to $50
4 Aug 21
News, Upgrades, Price Target, Analyst Ratings
Truist Securities analyst Joon Lee upgrades Global Blood Therapeutics (NASDAQ:GBT) from Hold to Buy and raises the price target from $45 to $50.
Global Blood Therapeutics Q2 EPS $(1.12) Beats $(1.19) Estimate, Sales $47.55M Beat $43.84M Estimate
3 Aug 21
Earnings, News
Global Blood Therapeutics (NASDAQ:GBT) reported quarterly losses of $(1.12) per share which beat the analyst consensus estimate of $(1.19) by 5.88 percent. This is a 30.23 percent decrease over losses of $(0.86) per
Stocks That Hit 52-Week Lows On Tuesday
3 Aug 21
News, Intraday Update, Markets, Movers, Trading Ideas
On Tuesday morning, 69 companies achieved new lows for the year.
Earnings Scheduled For August 3, 2021
3 Aug 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.

Press releases

Pro users get this 30m faster
GBT Announces New Employment Inducement Grants
7 Oct 21
Press Releases
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on October 1, 2021, the compensation committee of GBT's board of directors
GBT Announces New Employment Inducement Grants
9 Sep 21
Press Releases
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on September 1, 2021, the compensation committee of GBT's board of directors
GBT and Sickle Cell Disease Association of America to Host 10th Annual Sickle Cell Disease (SCD) Therapeutics Conference
8 Sep 21
News, Health Care, Press Releases
SOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the
GBT Announces Participation in Upcoming Investor Conferences
2 Sep 21
News, Press Releases
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will participate in virtual fireside chats at the following investor
Thinking about buying stock in Global Blood Therapeutics, Cerus Corp, Coursera, Agrify Corp, or Invitae Corp?
4 Aug 21
Opinion, Press Releases
NEW YORK, Aug. 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GBT, CERS, COUR, AGFY, and NVTA.
GBT Reports Second Quarter 2021 Financial Results
3 Aug 21
Earnings, Press Releases
Achieved Oxbryta® (voxelotor) net revenues of $47.6 million, an increase of 51% year-over-year Continued progress toward potential Oxbryta pediatric label expansion in U.S. and marketing authorization in